HIG, General Catalyst target hematology; Fragmented healthcare IT market drives Ironleaf to back HCS
Friday, November 13, 2026 · first reported by PEI Private Equity
HIG and General Catalyst are targeting hematology, and Ironleaf is backing HCS amid a fragmented healthcare IT market.
- Firm
- HIG
- Stage
- Launch
- Asset class
- Private equity
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
See an error?
More on HIG
Everything on this firm →- Morgan Lewis advises Pantheon on $6 billion final close of global PE secondaries Fund VIIIMorgan Lewis
- The 81 Collection doubles fund size to $82m to target underserved US industriesAltAssets
- Phoenix Equity Partners beats hard cap with £570m Fund III close in just six monthsAltAssets +2
- ICG pulls in $7.6bn as flagship fund closes at record €12bnAlternative Credit Investor +1
- Apollo’s £5.7bn easyJet takeover wins shareholder approvalPrivate Equity Wire
- Advent seeks up to $500m in renewed Learning Lab salePrivate Equity Wire
Got news? Send it to us →